AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

Now may be an ideal time to buy stocks. Even if you don't have a lot of money that you can afford to invest, there are many ...

Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...

Results from a clinical trial showed that capivasertib plus the hormone therapy fulvestrant increased the time before the ...

Investors are nervous. As of 9:55 a.m. ET Wednesday morning, shares of Roche Holding ( RHHBY -2.81%) are down 2.3%, Eli Lilly ( LLY -4.38%) stock is off 3.2%, and AstraZeneca ( AZN -4.87%) is doing ...

The Institute of Cancer Research, London, which helped develop the drug, welcomed the move. A twice-a-day pill for the most ...

AstraZeneca Pharmaceuticals LP and a Christian sales specialist have agreed to settle his suit over the company’s failure to ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of p14,200.00. The ...

Today, we've recommended capivasertib (also called Truqap and made by AstraZeneca) with fulvestrant as an option for around 1,100 adults with hormone receptor (HR)-positive HER2-negative breast cancer ...

Listen to this article Mark T. Esser, vice president for vaccines and immune therapies at pharmaceutical giant AstraZeneca, will be the inaugural chief scientific officer and leader of the Paul and ...

Alex Kerr, UK economist at Capital Economics, said: “Based on the rise in gilt yields and the fall in interest rate ...